JP2009535644A - バイオマーカーを使用して疾患状況を同定するための方法および装置 - Google Patents

バイオマーカーを使用して疾患状況を同定するための方法および装置 Download PDF

Info

Publication number
JP2009535644A
JP2009535644A JP2009509959A JP2009509959A JP2009535644A JP 2009535644 A JP2009535644 A JP 2009535644A JP 2009509959 A JP2009509959 A JP 2009509959A JP 2009509959 A JP2009509959 A JP 2009509959A JP 2009535644 A JP2009535644 A JP 2009535644A
Authority
JP
Japan
Prior art keywords
biomarker
symptom
data
biomarker data
negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009509959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535644A5 (https=
Inventor
グライムス エフ． ランドール，
Original Assignee
プロビスタ ダイアグノスティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロビスタ ダイアグノスティクス， エルエルシー filed Critical プロビスタ ダイアグノスティクス， エルエルシー
Publication of JP2009535644A publication Critical patent/JP2009535644A/ja
Publication of JP2009535644A5 publication Critical patent/JP2009535644A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2009509959A 2006-05-01 2007-04-25 バイオマーカーを使用して疾患状況を同定するための方法および装置 Withdrawn JP2009535644A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/381,104 US20070255113A1 (en) 2006-05-01 2006-05-01 Methods and apparatus for identifying disease status using biomarkers
PCT/US2007/067418 WO2007130831A2 (en) 2006-05-01 2007-04-25 Methods and apparatus for identifying disease status using biomarkers

Publications (2)

Publication Number Publication Date
JP2009535644A true JP2009535644A (ja) 2009-10-01
JP2009535644A5 JP2009535644A5 (https=) 2011-06-30

Family

ID=38648787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509959A Withdrawn JP2009535644A (ja) 2006-05-01 2007-04-25 バイオマーカーを使用して疾患状況を同定するための方法および装置

Country Status (13)

Country Link
US (5) US20070255113A1 (https=)
EP (2) EP2016405B1 (https=)
JP (1) JP2009535644A (https=)
KR (1) KR20090024686A (https=)
CN (1) CN101479599A (https=)
AU (1) AU2007248299A1 (https=)
BR (1) BRPI0711148A2 (https=)
CA (1) CA2650872C (https=)
IL (1) IL195054A0 (https=)
MX (1) MX2008013978A (https=)
RU (1) RU2008147223A (https=)
WO (1) WO2007130831A2 (https=)
ZA (1) ZA200809968B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014121323A (ja) * 2012-12-21 2014-07-03 Stembios Technologies Inc 幹細胞による行為効果を評価する方法
JP2017516085A (ja) * 2014-04-08 2017-06-15 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
US10143710B2 (en) 2010-08-04 2018-12-04 StemBios Technologies, Inc. Somatic stem cells
US11492592B2 (en) 2012-12-06 2022-11-08 StemBios Technologies, Inc. Lgr5+ somatic stem cells
JP2023086821A (ja) * 2016-01-22 2023-06-22 オートレイシーズ，インク． 疾患診断を改善するシステム及び方法
JP2023156388A (ja) * 2013-03-14 2023-10-24 オートレイシーズ・インコーポレイテッド 測定分析物を使用する、疾患診断を改善するための方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US8440418B2 (en) 2008-11-18 2013-05-14 Ridge Diagnostics, Inc. Metabolic syndrome and HPA axis biomarkers for major depressive disorder
US20110245092A1 (en) * 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
WO2009114627A2 (en) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Inflammatory biomarkers for monitoring depression disorders
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
EP2471016A1 (en) * 2009-08-28 2012-07-04 Lexicor Medical Technology, LLC Systems and methods to identify a subgroup of adhd at higher risk for complicating conditions
US20150127378A1 (en) * 2012-02-11 2015-05-07 Yougene Corp. Systems for storing, processing and utilizing proprietary genetic information
JP6075973B2 (ja) * 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
EP2684513A1 (en) 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
US20140275294A1 (en) * 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
CN103279655A (zh) * 2013-05-20 2013-09-04 浙江大学 一种恶性肿瘤放化疗规范符合度的评估方法
CN105431853B (zh) 2013-05-23 2018-12-28 艾弗诺泰普有限责任公司 表型整合的社会研究数据库和方法
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
PL3084664T3 (pl) * 2013-12-16 2020-10-05 Philip Morris Products S.A. Układy i sposoby do przewidywania statusu palenia u osobnika
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
US11594311B1 (en) 2016-03-31 2023-02-28 OM1, Inc. Health care information system providing standardized outcome scores across patients
US11957897B2 (en) 2016-04-22 2024-04-16 Newton Howard Biological co-processor (BCP)
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
US20190302119A1 (en) * 2018-03-27 2019-10-03 Lawrence Abraham Cancer Diagnostic Metastasis Panel
US11967428B1 (en) * 2018-04-17 2024-04-23 OM1, Inc. Applying predictive models to data representing a history of events
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
LU100835B1 (en) * 2018-06-13 2019-12-13 Univ Muenster Westfaelische Wilhelms Novel biomarkers for recurrent tonsillitis
US11862346B1 (en) 2018-12-22 2024-01-02 OM1, Inc. Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
US20200395097A1 (en) * 2019-05-30 2020-12-17 Tempus Labs, Inc. Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
TWI740647B (zh) * 2020-09-15 2021-09-21 宏碁股份有限公司 疾病分類方法及疾病分類裝置
US20220223231A1 (en) * 2021-01-14 2022-07-14 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Improved Prognostics in Medical Imaging
KR102671925B1 (ko) * 2022-03-03 2024-06-03 인제대학교 산학협력단 파킨슨병 진단 방법 및 그 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197532B1 (en) * 1998-01-22 2001-03-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis and detection of breast cancer and other cancers
CA2300639A1 (en) * 1999-03-15 2000-09-15 Whitehead Institute For Biomedical Research Methods and apparatus for analyzing gene expression data
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6714925B1 (en) * 1999-05-01 2004-03-30 Barnhill Technologies, Llc System for identifying patterns in biological data using a distributed network
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US20030087865A1 (en) * 2001-07-13 2003-05-08 Whitehead Institute For Biomedical Research Leukemogenic transcription factors
US20030225526A1 (en) * 2001-11-14 2003-12-04 Golub Todd R. Molecular cancer diagnosis using tumor gene expression signature
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20040076974A1 (en) * 2002-04-01 2004-04-22 Kier Larry D. Liver necrosis predictive genes
US20050176057A1 (en) * 2003-09-26 2005-08-11 Troy Bremer Diagnostic markers of mood disorders and methods of use thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143710B2 (en) 2010-08-04 2018-12-04 StemBios Technologies, Inc. Somatic stem cells
US11492592B2 (en) 2012-12-06 2022-11-08 StemBios Technologies, Inc. Lgr5+ somatic stem cells
JP2014121323A (ja) * 2012-12-21 2014-07-03 Stembios Technologies Inc 幹細胞による行為効果を評価する方法
JP2023156388A (ja) * 2013-03-14 2023-10-24 オートレイシーズ・インコーポレイテッド 測定分析物を使用する、疾患診断を改善するための方法
JP7603115B2 (ja) 2013-03-14 2024-12-19 オートレイシーズ・インコーポレイテッド 測定分析物を使用する、疾患診断を改善するための方法
JP2017516085A (ja) * 2014-04-08 2017-06-15 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
JP2023086821A (ja) * 2016-01-22 2023-06-22 オートレイシーズ，インク． 疾患診断を改善するシステム及び方法

Also Published As

Publication number Publication date
EP2016405A2 (en) 2009-01-21
US20110077931A1 (en) 2011-03-31
CA2650872C (en) 2018-04-24
BRPI0711148A2 (pt) 2011-08-23
EP2016405A4 (en) 2012-10-03
US20070254369A1 (en) 2007-11-01
MX2008013978A (es) 2009-02-19
EP2016405B1 (en) 2017-09-27
KR20090024686A (ko) 2009-03-09
CN101479599A (zh) 2009-07-08
AU2007248299A1 (en) 2007-11-15
EP3318995A1 (en) 2018-05-09
US20070255113A1 (en) 2007-11-01
CA2650872A1 (en) 2007-11-15
ZA200809968B (en) 2009-08-26
US20210041440A1 (en) 2021-02-11
IL195054A0 (en) 2009-08-03
WO2007130831A2 (en) 2007-11-15
US20130060549A1 (en) 2013-03-07
WO2007130831A3 (en) 2008-10-30
RU2008147223A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
US20210041440A1 (en) Methods and apparatus for identifying disease status using biomarkers
US11651189B2 (en) Methods and systems of evaluating a risk of a gastrointestinal cancer
Lacher et al. Biological variation of laboratory analytes based on the 1999-2002 National Health and Nutrition Examination Survey
CN105229471B (zh) 用于基于生物化学标记分析确定先兆子痫风险的系统和方法
US20190018930A1 (en) Method for building a database
Marakala Head and neck cancer biomarkers: Systematic review and meta-analysis
JP7543251B2 (ja) アミロイドベータの脳内への蓄積の評価を補助する方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置
CN116779077A (zh) 基于体检标志物构建生物学年龄及衰老评价的方法及系统
Yucel et al. The effect of lactate/albumin ratio on mortality in patients with sepsis
Tully et al. Operating characteristics of depression and anxiety disorder phenotype dimensions and trait neuroticism: a theoretical examination of the fear and distress disorders from the Netherlands study of depression and anxiety
CN115698712A (zh) 预测类风湿关节炎的疾病进展的方法
CN119694566A (zh) 基于Ai的脓毒血症的化学指标检测系统
CN121002198A (zh) 用于鉴别一种或多种预测性生物标志物的人工智能
KR20230163420A (ko) 치매의 장래의 발증 리스크의 평가 방법
Vrbanic et al. Intracranial haemorrhage and falls: cause or effect?
Suzuki et al. C-reactive protein and lactate dehydrogenase are useful biomarkers for predicting the requirement for oxygen therapy in outpatients with coronavirus disease 2019
WO2009108196A1 (en) Methods and apparatus for identifying disease status using biomarkers
TW202418295A (zh) 癌症進展判別方法及其系統
CN121641441A (zh) 青少年抑郁障碍辅助诊断或诊断模型的构建方法、装置、存储介质和设备
WO2024200489A1 (en) Blood biomarkers for monitoring changes in the amount of visceral adipose tissue
CN121613116A (zh) 青少年抑郁障碍诊断标志物及抑郁障碍诊断模型及其应用
Cullen The application of predictive statistical modelling in the investigation of suspected classical Myeloproliferative Neoplasms
Pestana Study of biomarkers in Multiple Myeloma: a statistical approach for longitudinal assessment of extracellular vesicles and its prognostic value
CN121324665A (zh) 一种生物标志物在制备用于预测ics治疗copd稳定期患者疗效的试剂或试剂盒中的应用
CN115527674A (zh) 一种健康管理系统、方法及电子设备

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100420

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110902

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110906